biostudies-literatureYang KLShin Kong Wu Ho-Su Memorial Hospital18https://www.ebi.ac.uk/biostudies/studies/S-EPMC7819176biostudies-literatureUnknown16(1)<h4>Background</h4>To investigate maximum tolerated dose (MTD) of axitinib, a selective vascular endothelial growth factor receptor 1-3 inhibitor, in combination with radiotherapy (RT) for advanced hepatocellular carcinoma (HCC).<h4>Methods</h4>This phase I study followed the rule of traditional 3 + 3 design. Major eligibility included: (1) patients with advanced HCC unsuitable for surgery, radiofrequency ablation or transarterial chemoembolization, or who failed after prior local-regional treatment; (2) failure on sorafenib or no grant for sorafenib from health insurance system. Eligible patients with advanced HCC received axitinib for total 8 weeks during and after RT. Three cohorts with axitinib dose escalation were planned: 1 mg twice daily (level I), 2 mg twice daily (level II) and 3 Radiation oncology (London, England)Axitinib in combination with radiotherapy for advanced hepatocellular carcinoma: a phase I clinical trial.PMC7819176SKH-8302-106-DR-27Huang YYHuang SCKo HLChi KHLin YMChi MSYang KLfalseAxitinib in combination with radiotherapy for advanced hepatocellular carcinoma: a phase I clinical trial.<h4>Background</h4>To investigate maximum tolerated dose (MTD) of axitinib, a selective vascular endothelial growth factor receptor 1-3 inhibitor, in combination with radiotherapy (RT) for advanced hepatocellular carcinoma (HCC).<h4>Methods</h4>This phase I study followed the rule of traditional 3 + 3 design. Major eligibility included: (1) patients with advanced HCC unsuitable for surgery, radiofrequency ablation or transarterial chemoembolization, or who failed after prior local-regional treatment; (2) failure on sorafenib or no grant for sorafenib from health insurance system. Eligible patients with advanced HCC received axitinib for total 8 weeks during and after RT. Three cohorts with axitinib dose escalation were planned: 1 mg twice daily (level I), 2 mg twice daily (level II) and 3 2021-01-01T00:00:00Z2021 Jan2025-04-27T00:43:21.48Z2021-02-21T01:54:59ZS-EPMC78191763347266610.1186/s13014-020-01742-w